Needham & Company LLC Cuts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $18.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price trimmed by Needham & Company LLC from $20.00 to $18.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the company. JMP Securities raised their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a research report on Wednesday, October 15th. Evercore ISI reissued an “in-line” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 26th. Zacks Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, TD Cowen initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

BioCryst Pharmaceuticals Stock Down 2.0%

Shares of BCRX stock opened at $7.03 on Tuesday. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -39.05 and a beta of 1.09. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The company’s 50 day moving average is $7.47 and its 200 day moving average is $8.67.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The business had revenue of $159.40 million during the quarter, compared to analyst estimates of $162.91 million. During the same quarter in the previous year, the business earned ($0.07) earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the sale, the director owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BCRX. Arrowstreet Capital Limited Partnership grew its holdings in shares of BioCryst Pharmaceuticals by 2,103.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after buying an additional 4,084,403 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock worth $32,441,000 after acquiring an additional 3,606,566 shares during the period. Millennium Management LLC grew its stake in BioCryst Pharmaceuticals by 382.6% during the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after purchasing an additional 3,022,769 shares during the last quarter. Qube Research & Technologies Ltd grew its stake in BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock valued at $21,266,000 after purchasing an additional 1,432,824 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at about $10,677,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.